DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/vgdk75/gtxs_capesaris) has announced the addition of the "GTx's Capesaris - A novel medical castration method" report to their offering.

Capesaris is an oral selective estrogen receptor modulator (SERM) that GTx is developing as a first-line androgen deprivation therapy (ADT) in advanced prostate cancer. By utilizing this approach, GTx hopes that use will be devoid of many of the adverse effects of historical medical castration products such as diethylstilbestrol (DES, an estrogen replacement therapy), and the luteinizing hormone receptor hormone (LHRH) agonists that form the current standard of care. This report explores the validity of that premise, the probability of phase III success, the regulatory path to approval, and the market into which it will launch, if successful.

Key Topics Covered:

INTRODUCTION AND BACKGROUND

1. Prostate cancer

- Epidemiology

- Clinical presentation, diagnosis, and staging

- Current treatments

2. GTX-758 (CAPESARIS)

See the original post here:
Research and Markets: GTx's Capesaris - A Novel Medical Castration Method

Comments are closed.